For more information, please see our News and SEC Filings sections.
Blepharitis is a disease characterized by inflammation of the lid margin that is common, complex, and has a multifactorial etiology. Blepharitis coexists with other common ocular surface conditions and is often under-diagnosed and misdiagnosed in general clinical practice.
Currently, there are no FDA-approved products indicated for the treatment of blepharitis. Patients have limited treatment options, which include warm compresses, lid hygiene, topical antibiotic ointments and topical steroids or oral antibiotics, when the condition is exacerbated.
AZASITE is approved by the FDA for the treatment of bacterial conjunctivitis in adults and children one year of age and older. AZASITE is a topical anti-infective, in which azithromycin is formulated into an ophthalmic solution utilizing DURASITE®, a novel ocular drug delivery system. Azithromycin is a semi-synthetic antibiotic that is derived from erythromycin and since 1992, has been available via oral administration by Pfizer Inc. under the trade name Zithromax®.
In February 2007, Inspire entered into an exclusive licensing agreement with InSite Vision Incorporated for the U.S. and Canadian commercialization of AZASITE.
Denufosol tetrasodium inhalation solution for cystic fibrosis - Phase 3
(diquafosol tetrasodium ophthalmic solution) 2% for dry eye - Phase 3; Approvable
(azithromycin ophthalmic solution) 1% for blepharitis - Phase 2
INS115644 and INS117548 for glaucoma - Phase 1
© Inspire Pharmaceuticals 2010 All Rights Reserved
Terms of Use Legal Notices
Page Updated on: 5/6/2010
